Scott Davies Sells 323 Shares of Illumina (NASDAQ:ILMN) Stock

Illumina, Inc. (NASDAQ:ILMN) insider Scott Davies sold 323 shares of the stock in a transaction on Friday, December 12th. The shares were sold at an average price of $136.09, for a total transaction of $43,957.07. Following the transaction, the insider owned 17,887 shares in the company, valued at $2,434,241.83. This trade represents a 1.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Illumina Price Performance

Shares of NASDAQ ILMN opened at $129.56 on Thursday. The company has a current ratio of 1.43, a quick ratio of 1.12 and a debt-to-equity ratio of 0.42. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $153.06. The business has a 50 day simple moving average of $116.72 and a 200-day simple moving average of $103.77. The company has a market capitalization of $19.80 billion, a price-to-earnings ratio of 29.05, a price-to-earnings-growth ratio of 2.35 and a beta of 1.44.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share for the quarter, topping analysts’ consensus estimates of $1.16 by $0.18. Illumina had a net margin of 16.40% and a return on equity of 29.21%. The company had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.07 billion. During the same period in the prior year, the company earned $1.14 earnings per share. The firm’s revenue was up .4% compared to the same quarter last year. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. As a group, equities research analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. UBS Group raised their price target on Illumina from $110.00 to $120.00 and gave the stock a “neutral” rating in a report on Friday, October 31st. Zacks Research upgraded Illumina from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 2nd. Evercore ISI boosted their price target on shares of Illumina from $132.00 to $142.00 and gave the company an “outperform” rating in a report on Friday, October 31st. Robert W. Baird set a $109.00 price objective on shares of Illumina in a report on Friday, October 31st. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Illumina in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, thirteen have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $117.19.

Institutional Trading of Illumina

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Rise Advisors LLC increased its position in shares of Illumina by 173.6% during the 1st quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock valued at $28,000 after purchasing an additional 224 shares during the period. Parkside Financial Bank & Trust boosted its position in shares of Illumina by 65.7% during the 2nd quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock valued at $28,000 after purchasing an additional 115 shares in the last quarter. Quent Capital LLC acquired a new position in shares of Illumina in the 3rd quarter worth approximately $29,000. Quarry LP bought a new stake in shares of Illumina in the 3rd quarter worth approximately $32,000. Finally, Aster Capital Management DIFC Ltd acquired a new stake in Illumina during the third quarter valued at approximately $33,000. 89.42% of the stock is currently owned by institutional investors.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.